This trial is active, not recruiting.

Conditions head and neck cancer, colon cancer
Treatments head and neck, colon- closed as of may 2014
Phase phase 1/phase 2
Targets EGFR, KRAS
Sponsor howard safran
Collaborator Fatima Memorial Hospital
Start date May 2012
End date March 2015
Trial size 63 participants
Trial identifier NCT01744340, BrUOG 254


The purpose of this study is to determine if the full dose of eribulin mesylate can be safely given with the full dose of cetuximab. The activity of the combination of eribulin mesylate and cetuximab on recurrent head and neck cancer and colon cancer will also be assessed.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Cetuximab, 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly there after Eribulin Mesylate 1.4mg/m2
head and neck
Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle
Eribulin Mesylate: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle
colon- closed as of may 2014
Eribulin Mesylate: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle

Primary Outcomes

Toxicity of eribulin mesylate combined with full dose cetuximab for patients with advanced head and neck cancer and colon cancer.
time frame: From beginning of treatment to 30 days post being off drug, an expected average of 6 months

Secondary Outcomes

Response rate (whether patient's disease is progressing or being controlled) of patients with head and neck cancer treated with eribulin mesylate and cetuximab.
time frame: From beginning of treatment to progression of disease, for an expected average of 1 year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria - Histologically or cytologically confirmed advanced squamous cell cancer of the head and neck with progression after at least one prior therapy. (Chemoradiation is considered one line of therapy). Patients with unknown Head and Neck primaries are also eligible - In the dose escalation cohorts, patients with advanced colon adenocarcinoma with wild-type kras who have previously received at least two lines of therapy for advanced disease are eligible- No longer applicable post February 2013 as all patients have been enrolled to the dose escalation phase - In the expansion phase for patients with advanced colorectal cancer, only patients with mutated kras who have previously received at least two lines of therapy for metastatic disease will be eligible. Pathology report from diagnosis and report documenting KRAS status to be sent to BrUOG. No longer applicable as this phase of the study has been closed as of 5/6/2014 secondary to the lack of efficacy and activity of the single agent. - Life expectancy of at least 3 months - Patients must be aged 18 years or older - Patients with measurable tumors according to RECIST . - Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 - No severe concurrent illness that would interfere with protocol therapy. - Patients must have adequate renal function as evidenced by ≤1.5 mg/dL or creatinine clearance > 40 mL/minute (min). - Patients must have adequate bone marrow function as evidenced by absolute neutrophil count (ANC) > 1.5 x 109/L and platelet count > 100 x 109/L. - Patients must have adequate hepatic function as evidenced by bilirubin ≤ 1.5 times the upper limit of normal (ULN) and alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 3 x ULN (in the case of liver metastases ALT and AST ≤ 5 x ULN). - Resolution of all chemotherapy or radiation-related toxicities to Grade 1 severity or below, except for alopecia. - Patients must be willing and able to comply with the study protocol for the duration of the study. - Patients must give written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice. - No other active invasive malignancy unless disease free for at least 2 years. Exclusion Criteria - For Head and Neck patients, no progression while receiving an EGFR inhibitor or within 6 months of stopping treatment with an EGFR inhibitor. - Patients who received chemotherapy or investigational therapy within 3 weeks before treatment initiation. Radiation must be completed within 2 weeks before treatment initiation. - Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative. - Patients who participated in a prior eribulin mesylate clinical trial, whether or not they received eribulin mesylate. - Patients with other significant disease or disorders that, in the investigator's opinion, would exclude the patient from the study. - Women who are pregnant or breast-feeding; women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test; women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator. Peri-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. - Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (e.g., radiologic) and/or symptoms of brain metastases must be stable for at least 4 weeks. - Grade 2 or worse neuropathy. - Significant cardiovascular impairment (history of congestive heart failure > NYHA G II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia. - QTc > 500 msec

Additional Information

Official title A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer With an Expansion Cohort For Head and Neck Cancer: A Brown University Oncology Research Group Study
Principal investigator Howard Safran, MD
Description To determine if eribulin mesylate, up to a maximum dose of 1.4 mg/m2 day 1 and 8 of a 21 day cycle, can be safely combined with full dose cetuximab for patients with advanced head and neck cancer and colon cancer
Trial information was received from ClinicalTrials.gov and was last updated in March 2015.
Information provided to ClinicalTrials.gov by Brown University.